Vis enkel innførsel

dc.contributor.authorRamberg, Cathrine
dc.contributor.authorWilsgård, line
dc.contributor.authorLatysheva, Nadezhda
dc.contributor.authorBrækkan, Sigrid Kufaas
dc.contributor.authorHindberg, Kristian
dc.contributor.authorSovershaev, Timofey
dc.contributor.authorSnir, Omri
dc.contributor.authorHansen, John Bjarne
dc.date.accessioned2022-01-25T13:43:13Z
dc.date.available2022-01-25T13:43:13Z
dc.date.issued2021-12-20
dc.description.abstractBackground - Negatively charged procoagulant phospholipids, phosphatidylserine (PS) in particular, are vital to coagulation and expressed on the surface membrane of extracellular vesicles. No previous study has investigated the association between plasma procoagulant phospholipid clotting time (PPL<sub>CT</sub>) and future risk of venous thromboembolism (VTE).<p> <p>Objectives - To investigate the association between plasma PPL<sub>CT</sub> and the risk of incident VTE in a nested case-control study.<p> <p>Methods - We conducted a nested case-control study in 296 VTE patients and 674 age- and sex-matched controls derived from a general population cohort (The Tromsø Study 1994–2007). PPL<sub>CT</sub> was measured in platelet-free plasma using a modified factor Xa-dependent clotting assay. Logistic regression was used to estimate odds ratio (OR) with 95% confidence intervals (CI) for VTE with PPL<sub>CT</sub> modelled as a continuous variable across quartiles and in dichotomized analyses.<p> <p>Results - There was a weak inverse association between plasma PPL<sub>CT</sub> and risk of VTE per 1 standard deviation increase of PPL<sub>CT</sub> (OR 0.93, 95% CI 0.80–1.07) and when comparing those with PPL<sub>CT</sub> in the highest quartile (OR 0.89, 95% CI 0.60–1.30) with those in the lowest quartile. Subjects with PPL<sub>CT</sub> >95th percentile had substantially lowered OR for VTE (OR 0.35, 95% CI 0.13–0.81). The inverse association was stronger when the analyses were restricted to samples taken shortly before the event. The risk estimates by categories of plasma PPL<sub>CT</sub> were similar for deep vein thrombosis and pulmonary embolism.<p> <p>Conclusion - Our findings suggest that high plasma PPL<sub>CT</sub> is associated with reduced risk of VTE.en_US
dc.identifier.citationRamberg, Wilsgård, Latysheva, Brækkan, Hindberg, Sovershaev, Snir, Hansen. Plasma procoagulant phospholipid clotting time and venous thromboembolism risk. Research and Practice in Thrombosis and Haemostasis. 2021;5(8):1-9en_US
dc.identifier.cristinIDFRIDAID 1987100
dc.identifier.doi10.1002/rth2.12640
dc.identifier.issn2475-0379
dc.identifier.urihttps://hdl.handle.net/10037/23804
dc.language.isoengen_US
dc.publisherWileyen_US
dc.relation.journalResearch and Practice in Thrombosis and Haemostasis
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.titlePlasma procoagulant phospholipid clotting time and venous thromboembolism risken_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel